The Epstein-Barr virus (EBV), which infects over 90 percent of people during their lifetime, causes diseases such as infectious mononucleosis (also known as Pfeiffer's glandular fever) and secondary diseases like multiple sclerosis, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and certain tumors. A vaccine candidate based on non-infectious, EBV-derived virus-like particles, which has proven highly effective in animal studies, is being manufactured under Good Manufacturing Practice (GMP) conditions for clinical trials in humans. This vaccine candidate is being developed as part of the start-up EBViously, a DZIF-supported spin-off from Helmholtz Munich.